AVANIR Pharmaceuticals Income Statement
View: Annual | Quarterly
| Sep 08 | Sep 07 | Sep 06 | |
|---|---|---|---|
| Revenue | 7.0 | 9.2 | 15.2 |
| Cost of Goods Sold | 0.3 | 4.6 | 7.9 |
| Gross Profit | 6.7 | 4.6 | 7.3 |
| Gross Profit Margin | 96.1% | 49.6% | 47.9% |
| SG&A Expense | 10.6 | 20.8 | 38.1 |
| Depreciation & Amortization | 0.7 | 2.8 | 3.9 |
| Operating Income | (15.4) | (27.1) | (58.2) |
| Operating Margin | -- | -- | -- |
| Nonoperating Income | 2.3 | 1.6 | 0.0 |
| Nonoperating Expenses | 0.7 | -- | -- |
| Income Before Taxes | (15.9) | (28.4) | (58.9) |
| Income Taxes | 0.0 | 0.0 | 0.0 |
| Net Income After Taxes | (15.9) | (28.4) | (58.9) |
| Continuing Operations | (19.0) | (28.4) | (58.9) |
| Discontinued Operations | (1.6) | 7.4 | -- |
| Total Operations | (20.5) | (20.9) | (58.9) |
| Total Net Income | (20.5) | (20.9) | (58.9) |
| Net Profit Margin | -- | -- | -- |
| Diluted EPS from Total Net Income ($) | (0.30) | (0.53) | (2.04) |
| Dividends per Share | 0.00 | 0.00 | 0.00 |
© 2009 Morningstar, Inc. Financial Data provided by
